Biocon gets eight observations for two new units in Bengaluru
Biotechnology major, Biocon, said it has received a total of eight observations from the US health regulator for its two new biologics manufacturing facilities in Bengaluru.
The United States Food and Drug Administration (USFDA) conducted a pre-approval inspection (PAI) at two of the company’s new biologics manufacturing facilities in Bengaluru from September 10-19, 2019, Biocon said in a filing to the stock exchange. The inspection included a new drug substance and a drug product unit, it added.
“At the conclusion of the inspection, we received a Form 483 with four observations for the new drug substance facility, three observations for the new drug product facility and one general observation,” a Biocon spokesperson said in a statement. The company is confident of addressing these observations effectively through a Corrective and Preventive Action (CAPA) plan, expeditiously, it added.
The company did not provide any details about the observations made by the US regulator.
You May Interested In
High Quality β-Nicotinamide adenine dinucleotide CAS 53-84-9 NADwith ready stock and best price
$3/UNIT FOB
2026-09-24
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Commercialisation plans for insulin glargine unchanged: Biocon
-
Biocon's Malaysia manufacturing facility receives EU GMP nod
-
The US Fertilizer Probe Is About More Than Pricing — It Is About Power
-
TAKAI Is Being Sold as More Than an Insecticide, and That Is the Point
-
From Painting Walls to Total Collapse: The RMB 152 Million Debt That Tore Off the Last Veil of Asia Chuangneng’s Paint Empire
-
Keshun Enters Industrial Coatings: Waterproofing Leader Seeks Growth Beyond Real Estate
-
Why Did Chemical Raw Materials Unexpectedly Escape the Latest Round of U.S. 301 Tariffs on 60 Economies?
-
“Did They Just Buy a Money Printer for ¥288 Million?”: Yip’s Chemical’s Bold Bet on Green Tech—Is This a Genuine Transformation or Just Another Story for the Stock Market?
-
Iran's Only MDI/TDI Plant Attacked, Middle East Supply Nearly Zero, Global Gap Widens
-
India Targets Fake Drug Packaging
Recommend Reading
-
![India’s Pharma Cost Problem Gets Worse]()
India’s Pharma Cost Problem Gets Worse
-
![Metso Expands Wear Parts Capacity in China with New Rubber Factory in Quzhou]()
Metso Expands Wear Parts Capacity in China with New Rubber Factory in Quzhou
-
![Saudi Aramco Suspends Next-Month Crude Supply to Some European Refineries]()
Saudi Aramco Suspends Next-Month Crude Supply to Some European Refineries
-
![“Zero Tariff Is Not a Get-Out-of-Jail-Free Card”: Hainan’s Full Customs Closure—Boon or Trap for the Chemical Industry?]()
“Zero Tariff Is Not a Get-Out-of-Jail-Free Card”: Hainan’s Full Customs Closure—Boon or Trap for the Chemical Industry?
-
![Drone Strike Hits Moscow Oil Refinery, Sparking Fire at Key Fuel Facility]()
Drone Strike Hits Moscow Oil Refinery, Sparking Fire at Key Fuel Facility
-
![Applications of Aluminium Orthophosphate]()
Applications of Aluminium Orthophosphate
-
![Escalation of Conflict in the Middle East Drives Oil Prices Above $110; Supply Concerns Continue to Intensify]()
Escalation of Conflict in the Middle East Drives Oil Prices Above $110; Supply Concerns Continue to Intensify
-
![Business Society September 21, 2026 Toluene Trend Analysis: Volatile and Bearish]()
Business Society September 21, 2026 Toluene Trend Analysis: Volatile and Bearish
-
![Raw Material Side Shows Resilience—PTA Prices Surge Over 3% in a Single Day]()
Raw Material Side Shows Resilience—PTA Prices Surge Over 3% in a Single Day
-
![Business Society September 20, 2026 Hydrofluoric Acid Trend Analysis: Sideways Consolidation]()
Business Society September 20, 2026 Hydrofluoric Acid Trend Analysis: Sideways Consolidation
